Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
36 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Lentigen Corporation - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Lentigen Corporation - Product Pipeline Review - 2014', provides an overview of the Lentigen Corporation's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Lentigen Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Lentigen Corporation including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Lentigen Corporation's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Lentigen Corporation's pipeline products Reasons to buy - Evaluate Lentigen Corporation's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Lentigen Corporation in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Lentigen Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Lentigen Corporation and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Lentigen Corporation - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Lentigen Corporation and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Lentigen Corporation Snapshot 5 Lentigen Corporation Overview 5 Key Information 5 Key Facts 5 Lentigen Corporation - Research and Development Overview 6 Key Therapeutic Areas 6 Lentigen Corporation - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 Lentigen Corporation - Pipeline Products Glance 13 Lentigen Corporation - Clinical Stage Pipeline Products 13 Phase I Products/Combination Treatment Modalities 13 Lentigen Corporation - Early Stage Pipeline Products 14 Preclinical Products/Combination Treatment Modalities 14 Discovery Products/Combination Treatment Modalities 15 Lentigen Corporation - Drug Profiles 16 LG-631 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 LG-723 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 erythropoietin 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 LG-1041 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 LG-1231 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 LG-611 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 LG-811 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 LG-889 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 LG-970 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 rituximab biosimilar 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 LG-888 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Lentigen Corporation - Pipeline Analysis 28 Lentigen Corporation - Pipeline Products by Target 28 Lentigen Corporation - Pipeline Products by Route of Administration 29 Lentigen Corporation - Pipeline Products by Molecule Type 30 Lentigen Corporation - Pipeline Products by Mechanism of Action 31 Lentigen Corporation - Recent Pipeline Updates 32 Lentigen Corporation - Dormant Projects 33 Lentigen Corporation - Locations And Subsidiaries 34 Head Office 34 Appendix 35 Methodology 35 Coverage 35 Secondary Research 35 Primary Research 35 Expert Panel Validation 35 Contact Us 36 Disclaimer 36
List of Tables Lentigen Corporation, Key Information 5 Lentigen Corporation, Key Facts 5 Lentigen Corporation - Pipeline by Indication, 2014 8 Lentigen Corporation - Pipeline by Stage of Development, 2014 9 Lentigen Corporation - Monotherapy Products in Pipeline, 2014 10 Lentigen Corporation - Partnered Products in Pipeline, 2014 11 Lentigen Corporation - Partnered Products/ Combination Treatment Modalities, 2014 12 Lentigen Corporation - Phase I, 2014 13 Lentigen Corporation - Preclinical, 2014 14 Lentigen Corporation - Discovery, 2014 15 Lentigen Corporation - Pipeline by Target, 2014 28 Lentigen Corporation - Pipeline by Route of Administration, 2014 29 Lentigen Corporation - Pipeline by Molecule Type, 2014 30 Lentigen Corporation - Pipeline Products by Mechanism of Action, 2014 31 Lentigen Corporation - Recent Pipeline Updates, 2014 32 Lentigen Corporation - Dormant Developmental Projects,2014 33
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.